Education
About Us
Working with TipRanks
Follow Us
Santen Pharmaceutical Co Ltd (SNPHF)
OTHER OTC:SNPHF
SNPHF Stock Chart & Stats
$10.60
$0.00(0.00%)
At close: 4:00 PM EST
$10.60
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$8.69 - $12.72
Previous CloseN/A
Volume1.00K
Average Volume (3M)0.00
Market Cap
$3.52B
Enterprise Value$527.72B
Total Cash (Recent Filing)$61.54B
Total Debt (Recent Filing)$36.15B
Price to Earnings (P/E)18.2
Beta-0.11
Next Earnings
May 12, 2026EPS Estimate
0.21Next Dividend Ex-DateN/A
Dividend Yield2.47%
Share Statistics
EPS (TTM)0.16
Shares Outstanding322,273,960
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.32
Price to Book (P/B)1.73
Price to Sales (P/S)1.65
P/FCF Ratio9.11
Enterprise Value/Market Cap149.98
Enterprise Value/Revenue1.83
Enterprise Value/Gross Profit3.36
Enterprise Value/Ebitda8.60
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.64
Revenue Forecast (FY)$1.87B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and a large equity base provide durable financial flexibility to fund R&D, support launches, and withstand temporary revenue softness. This conservative capital structure reduces refinancing risk and preserves optionality for strategic investments over the next several quarters.
Rebound To Profitable MarginsA return to consistent profitability and double-digit net margins indicates the company has restored earnings power after 2023. Sustainable margins reflect durable cost control and pricing on core ophthalmic products, supporting free cash generation and reinvestment capacity over the medium term.
Specialized Ophthalmology Franchise & Global ReachA focused ophthalmology business and established branded franchises create competitive advantages in product expertise, physician relationships, and lifecycle management. Geographic presence beyond Japan supports diversified revenue streams and allows label expansions and rollouts to extend product life cycles sustainably.
Bears Say
Declining Revenue TrendOngoing revenue declines reduce operating leverage and can erode long-term growth potential if not reversed. Persistent top-line weakness pressures margins, limits reinvestment capacity, and raises execution risk for product launches and lifecycle extensions over the next several quarters.
Weakening Cash Flow MomentumA step-down in operating and free cash flow signals higher working-capital needs or elevated investment spending, reducing excess liquidity. Weaker cash conversion constrains funding for R&D, marketing, or dividends and lowers resilience to prolonged sales softness over 2–6 months.
Exposure To Japan Pricing/regulatory RiskHeavy exposure to Japan's regulated reimbursement framework creates a structural sensitivity to price revisions and policy changes. Because domestic sales drive core revenue, adverse pricing or reimbursement decisions could materially pressure top-line durability and margin sustainability over the medium term.
Santen Pharmaceutical Co News
SNPHF FAQ
What was Santen Pharmaceutical Co Ltd’s price range in the past 12 months?
Santen Pharmaceutical Co Ltd lowest stock price was $8.69 and its highest was $12.72 in the past 12 months.
What is Santen Pharmaceutical Co Ltd’s market cap?
Santen Pharmaceutical Co Ltd’s market cap is $3.52B.
When is Santen Pharmaceutical Co Ltd’s upcoming earnings report date?
Santen Pharmaceutical Co Ltd’s upcoming earnings report date is May 12, 2026 which is in 70 days.
How were Santen Pharmaceutical Co Ltd’s earnings last quarter?
Santen Pharmaceutical Co Ltd released its earnings results on Feb 05, 2026. The company reported $0.157 earnings per share for the quarter, missing the consensus estimate of $0.188 by -$0.031.
Is Santen Pharmaceutical Co Ltd overvalued?
According to Wall Street analysts Santen Pharmaceutical Co Ltd’s price is currently Overvalued.
Does Santen Pharmaceutical Co Ltd pay dividends?
Santen Pharmaceutical Co Ltd pays a Semiannually dividend of $0.123 which represents an annual dividend yield of 2.47%. See more information on Santen Pharmaceutical Co Ltd dividends here
What is Santen Pharmaceutical Co Ltd’s EPS estimate?
Santen Pharmaceutical Co Ltd’s EPS estimate is 0.21.
How many shares outstanding does Santen Pharmaceutical Co Ltd have?
Santen Pharmaceutical Co Ltd has 322,273,960 shares outstanding.
What happened to Santen Pharmaceutical Co Ltd’s price movement after its last earnings report?
Santen Pharmaceutical Co Ltd reported an EPS of $0.157 in its last earnings report, missing expectations of $0.188. Following the earnings report the stock price went up 0.222%.
Which hedge fund is a major shareholder of Santen Pharmaceutical Co Ltd?
Currently, no hedge funds are holding shares in SNPHF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Santen Pharmaceutical Co Ltd
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.
Technical Analysis
Astellas Pharma
―
Menicon Co
―
Nipro
―
Tsubota Laboratory Incorporated
―
Japan Eyewear Holdings Co.,Ltd.
―
Ownership Overview
―
Insiders
6.25% Mutual Funds
― Other Institutional Investors
86.29% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---